HALO241220C50000
- 0.10
- 0.000.00%
Halozyme Therapeutics Newsroom
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
Corporate Candidates to Announce Accelerate Share Buybacks: Trivariate
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $77
Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $57
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Cuts Target Price to $57
Express News | Piper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $53
Halozyme Therapeutics (HALO) Is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $70
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $77
Top Gap Ups and Downs on Wednesday: EBAY, SOUN, STLA and More
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Sector Update: Health Care Stocks Rise Premarket Wednesday
Sector Update: Health Care
Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell